RET and non-small cell lung carcinoma: A response rate of 57% (95% CI: 46, 68%) was reported for a second specific inhibitor, pralsetinib, in a smaller cohort of 87 patients with RET fusion-positive advanced NSCLC who had previously received platinum chemotherapy and 70% (CI 95%: 50, 86%) in treatment naive patients with RET-fusion positive advanced NSCLC (7).